Adderall XR
Compare with other ADHD Medications
Compare
| Adderall XR |
VS |
ADHD Medications |
|
|
Basic Information |
| Generic Name |
|
Amphetamine And Dextroamphetamine |
9.5% ADHD Medications have Amphetamine and dextroamphetamine
|
| Class |
|
Cns Stimulants |
85.7% ADHD Medications have CNS Stimulants |
| Prescription Generic Available |
|
Yes |
61.9% ADHD Medications have Prescription Generic Available
|
| Pregnancy cat. |
|
C(US) |
85.7% ADHD Medications have C(US) |
| Approved Age |
|
3 And Older |
14.3% ADHD Medications have 3 and older
|
| Legal Status |
|
Schedule Ii (us) |
|
| WADA Category |
|
S6 - Stimulants |
|
| Dependence Liability |
|
High |
76.5% ADHD Medications have High
|
| Excretion |
|
Urinary |
68.4% ADHD Medications have urinary |
| Possible Side Effects |
|
Some Loss Of Appetite, Weight Loss, Sleep Problems, Irritability, Tics. |
|
|
|
|
Dosage, Usage and Forms |
| Routes (of administration) |
|
(medical) Oral, Insufflated, Intravenous |
|
| Dosage |
|
5 Mg Q Am–40 Mg Q Am |
|
| Maximum daily dose |
|
|
|
| Duration |
|
Long-acting |
52.4% ADHD Medications have Long-acting
|
| Duration - time |
|
10-14 H |
9.5% ADHD Medications have 10-14 h
|
|
|
Chemical Data |
| Molecular mass (g/mol) |
|
135.21 G/mol |
|
| Half Life |
|
|
|
| Formula |
|
C9H13N |
|
| Bioavailability |
|
Nasal 75%; Rectal 95-99%; Intravenous 100% |
|
| Protein binding |
|
|
|
| Metabolism |
|
Hepatic |
|